ARTICLE | Clinical News
Vpriv velaglucerase alfa regulatory update
March 1, 2010 8:00 AM UTC
FDA approved an NDA from Shire for Vpriv velaglucerase alfa to treat Type I Gaucher's disease. Shire plans to launch the glucocerebrosidase enzyme replacement therapy immediately. The wholesale acqui...